Pulse Biosciences (NASDAQ:PLSE) Rating Increased to Strong-Buy at Freedom Capmkts

Freedom Capmkts upgraded shares of Pulse Biosciences (NASDAQ:PLSE) to a strong-buy rating in a research note issued to investors on Wednesday,Zacks reports.

PLSE has been the subject of several other reports. Mizuho set a $45.00 target price on Pulse Biosciences in a research note on Monday, August 10th. Needham & Company LLC initiated coverage on Pulse Biosciences in a research note on Monday, August 17th. They issued a “buy” rating and a $58.00 price target on the stock. Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, September 6th. Oppenheimer reaffirmed an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Pulse Biosciences has an average rating of “Moderate Buy” and a consensus target price of $45.25.

Pulse Biosciences Stock Performance

Shares of NASDAQ:PLSE opened at $54.43 on Wednesday. Pulse Biosciences has a 52-week low of $12.56 and a 52-week high of $58.90. The company has a market capitalization of $3.77 billion, a P/E ratio of -46.13 and a beta of 1.63. The company has a 50-day simple moving average of $39.87 and a 200 day simple moving average of $28.84.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The business had revenue of $0.43 million for the quarter, compared to the consensus estimate of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. As a group, equities analysts forecast that Pulse Biosciences will post -1.29 earnings per share for the current year.

Insider Buying and Selling at Pulse Biosciences

In other news, COO Liane Teplitsky bought 1,036 shares of the stock in a transaction dated Wednesday, August 26th. The shares were bought at an average price of $48.23 per share, for a total transaction of $49,966.28. Following the completion of the purchase, the chief operating officer owned 1,036 shares in the company, valued at approximately $49,966.28. This trade represents a ? increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders purchased a total of 4,095 shares of company stock worth $199,931 in the last 90 days. 74.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. grew its position in Pulse Biosciences by 13.8% during the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after buying an additional 619 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in Pulse Biosciences by 63.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after acquiring an additional 680 shares in the last quarter. Osterweis Capital Management Inc. bought a new stake in shares of Pulse Biosciences during the 2nd quarter valued at $28,000. Alliancebernstein L.P. lifted its position in shares of Pulse Biosciences by 6.7% during the 3rd quarter. Alliancebernstein L.P. now owns 20,620 shares of the company’s stock valued at $365,000 after acquiring an additional 1,300 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Pulse Biosciences by 275.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after purchasing an additional 2,156 shares in the last quarter. 76.95% of the stock is owned by institutional investors and hedge funds.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.